Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,595.20GBp
6:40am EDT
Change (% chg)

0.00 (+0.00%)
Prev Close
1,595.20
Open
1,607.40
Day's High
1,608.00
Day's Low
1,587.20
Volume
1,460,619
Avg. Vol
7,299,359
52-wk High
1,648.80
52-wk Low
1,408.80

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.21
Market Cap(Mil.): £75,181.28
Shares Outstanding(Mil.): 4,918.63
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 38.75 29.30 32.55
EPS (TTM): 0.39 -- --
ROI: 7.58 14.23 13.82
ROE: 278.84 15.46 15.24

VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial

VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%.

Jun 17 2019

UPDATE 2-VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial

June 17 VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%.

Jun 17 2019

GSK pharma head flags need for speed in high-pressure drug market

LONDON Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

Jun 17 2019

GSK pharma head flags need for speed in high-pressure drug market

LONDON, June 17 Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.

Jun 17 2019

Germany's Stada buys six of GSK's consumer brands, eyes further deals

FRANKFURT Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe.

Jun 07 2019

Germany's Stada buys six of GSK's consumer brands, eyes further deals

FRANKFURT, June 7 Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe.

Jun 07 2019

GSK renews Zofran birth defect dismissal bid after Supreme Court ruling

GlaxoSmithKline PLC says the U.S. Supreme Court's recent ruling on how federal law can preempt state law product liability claims against drugmakers justifies delaying the first trial in lawsuits alleging its antinausea medication Zofran causes birth defects.

Jun 04 2019

GSK's Nucala wins European panel thumbs-up for self-administration

June 4 GlaxoSmithKline said on Tuesday it had won marketing approval from a European Medicines Agency (EMA) panel for its Nucala drug to be self-administered to treat severe asthma.

Jun 04 2019

U.S. Supreme Court won't review GSK generic Paxil suicide case

The U.S. Supreme Court on Tuesday turned away a challenge to an appeals court ruling that overturned a $3 million verdict against GlaxoSmithKline won by the widow of Stewart Dolin, a Reed Smith partner who killed himself after using a generic version of its antidepressant Paxil.

May 28 2019

UPDATE 1-GSK brings back bonuses for some sales reps

May 23 British drugmaker GlaxoSmithKline said on Thursday it will reintroduce incentive payments for sales representatives in some countries to retain talent after stopping them for years in the wake of scandals over illegal sales practices.

May 23 2019

Earnings vs. Estimates